Europe
The legal ruling, subject to appeal, protects the Swiss pharma giant’s revenue stream from the blockbuster drug Gilenya for a little bit longer.
“Joining the board will allow me to help guide and influence the development of a product from bench to bedside,” Franchimont told BioSpace. “I look forward to contributing to ongoing discussions on translation from bench science to the clinic, and ultimately to making real differences in the lives of patients.”
The new research hub will be called the London Discovery Research Centre and is expected to open by 2025.
Together the two companies will scour comprehensive medical and molecular data sets of thousands of chronic kidney disease patients to identify and then develop possible drugs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
Under terms of the deal, Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
Phase III clinical trials for Russia’s Sputnik V vaccine for COVID-19 began Wednesday, one day after the Russia Direct Investment Fund (RDIF) launched a new website to share the details of the vaccine with the public and scientists around the world.
It was a very busy week for clinical trial updates. Here’s a look.
Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the vaccine should it be approved, as well as a late-stage efficacy study in that country.
PRESS RELEASES